Martin, Karen E. http://orcid.org/0000-0003-0261-6709
Hammer, Quirin http://orcid.org/0000-0003-2968-6061
Perica, Karlo
Sadelain, Michel http://orcid.org/0000-0002-9031-8025
Malmberg, Karl-Johan http://orcid.org/0000-0002-8718-9373
Article History
Accepted: 5 March 2024
First Online: 24 April 2024
Competing interests
: K.-J.M. is a consultant at Fate Therapeutics. K.-J.M. has research support from Oncopeptides. K.-J.M. and Q.H. are consultants at Vycellix. All relationships have been approved by Oslo University Hospital, University of Oslo and Karolinska Institute. M.S. receives research support (for unrelated studies) from Fate Therapeutics and Takeda.